"Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study" by Mazyar Shadman

Selected Works of John M. Pagel, MD, PhD

Article

Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study

Blood (2016)

Mazyar Shadman, Fred Hutchinson Cancer Research Center
Ajay K Gopal, Fred Hutchinson Cancer Research Center
Oliver Press, Fred Hutchinson Cancer Research Center
David G. Maloney, Fred Hutchinson Cancer Research Center
Raya Mawad, Cancer Institute
Troy Wadsworth
Trevor W. Dennie
Karl Schultheiss
Kiarash Kojouri, Skagit Valley Hospital
Britt E Kammerer, Fred Hutchinson Cancer Research Center
John M. Pagel, Cancer Institute

Link

Disciplines

Publication Date

December 2, 2016

Citation Information

Mazyar Shadman, Ajay K Gopal, Oliver Press, David G. Maloney, et al.. "Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study" Blood Vol. 128 Iss. 22 (2016) p. 4396 - 4396
Available at: http://works.bepress.com/john-pagel/32/